By allowing the medication to do much of the metabolic work, patients can focus on developing healthier habits without feeling overwhelmed or discouraged
Currently, there are seven different approved GLP-1RAs on the market: liraglutide once daily, semaglutide once weekly, exenatide extended-release (ER) once weekly, dulaglutide once weekly, oral semaglutide once daily, exenatide twice daily, and lixisenatide once daily
clinical reports back up that early timing is common, as shown by Real-World Safety Concerns of Tirzepatide: A retrospective analysis of FAERS data published on September 9, 2025, reported that among 1,500 patients, 30% experienced nausea after starting tirzepatide
It is an alteration in the balance of prooxidant /antioxidant system in favour of prooxidant with attendant lethal effects with resultant damage to the cellular macromolecules (Fig